Corona inte antikroppar
Although immunocompromised people may not respond as well to the vaccine, there are no particular safety concerns. A booster dose may be given to adults and children from the age of 6 years, at least 3 months after primary vaccination with Spikevax, or another mRNA vaccine or an adenoviral vector vaccine. The study showed that Spikevax produced a comparable immune response in to year-olds to that seen in young adults aged 18 to 25 years , as measured by the level of antibodies against SARS-CoV In addition, none of the 2, children who received the vaccine developed COVID, compared with four of 1, children given a dummy injection.
Spikevax can be used during breast-feeding. Data from women who were breast-feeding after vaccination have not shown a fara of adverse effects in breast-fed babies. Half received the vaccine and half were given dummy injections. The trial showed a This means that the vaccine demonstrated a The trial also showed Another study showed that an additional dose of Spikevax increased the ability to produce antibodies against SARS-CoV-2 in organ transplant patients with severely weakened immune systems.
When a individ is given the vaccine, some of their cells will read the mRNA instructions and temporarily produce the spike protein. Allergic reactions hypersensitivity have been seen in people receiving the vaccine. It contains a molecule called mRNA which has instructions for making the spike protein. For more information about using Spikevax, including information about the adapted vaccines and doses for different age groups, see the package leaflet or consult a healthcare professional.
Therefore, Spikevax is also authorised as four adapted vaccines, with Spikevax JN. The originally authorised Spikevax is given in people from the age of 6 months as two injections, usually into the muscle of the upper arm, or the thigh in infants and young children, 28 days apart. The high efficacy was maintained across genders and ethnic groups. Although data in women in the first trimester of pregnancy are more limited, no increased risk of miscarriage was seen.
Adapted vaccines work in the same way as the original vaccine and are expected to maintain protection against the virus as they contain mRNA more closely matching circulating variants of the virus. In children from 6 months to 4 years of age, they are given as a single injection in those who have completed a primary vaccination course or have had COVID before, or as two injections 28 days apart in those who have not previously been vaccinated against COVID or had COVID The vaccines should be used according to official recommendations, issued at national level, by public health bodies.
Based on available data, vaccines adapted to target circulating strains of the virus are expected to elicit a strong immune response against these strains. Therefore, as for all vaccines, Spikevax, including the adapted vaccines, should be given beneath close medical supervision, with the appropriate medical treatment available in case of allergic reactions. If, later on, the person comes into contact with SARS-CoV-2, their immune system will recognise it and be ready to defend the body against it.
People did not know whether they received the vaccine or the dummy injections. After vaccination, the mRNA from the vaccine is broken down and removed from the body.
Hur ska jag tolka svaret på mitt antikroppstest?
No information are currently available regarding the use of the adapted vaccines in pregnant or breast-feeding women. These results allowed to conclude that the efficacy of Spikevax in children 12 to 17 years old is similar to that in adults. The effects of Spikevax were also investigated in a study involving over 3, children aged 12 to 17 years. An additional study involving three groups of children aged 6 months to beneath 2 years, 2 to 5 years and 6 to 11 years showed that Spikevax produced a comparable immune response in these age groups to that seen in ung adults aged 18 to 25 years , as measured by the level of antibodies against SARS-CoV These results indicate that the efficacy of Spikevax in children 6 months to 11 years old is similar to that in adults.
Severely immunocompromised people may be given an additional dose of Spikevax as part of their primary vaccination. People who have a severe allergic reaction when they are given a dose of one of the Spikevax vaccines should not receive subsequent doses.
The trial involved around 30, people in total. However, based on the similarity with the originally authorised Spikevax, including a comparable safety profile, the adapted vaccines can be used during pregnancy and breast-feeding. A large amount of data from pregnant women vaccinated with Spikevax during the second or third trimester of their pregnancy has been analysed and showed no increase in pregnancy complications.
Efficacy was calculated in around 28, people from 18 to 94 years of age who had no sign of previous infection.
Report Abuse
The main clinical trials for Spikevax included people of different ethnicities and genders. Spikevax is a vaccine for preventing coronavirus disease COVID in people from the age of 6 months. The most common side effects with Spikevax are usually mild or moderate and get better within a few days after vaccination. People who already know they have an allergy to one of the components of the vaccine listed in section 6 of the package leaflet should not receive the vaccine.
A very small number of cases of anaphylaxis severe allergic reaction have occurred.